Oral Alzheimer’s drug advances to Phase 2 trial.

“Asceneuron’s lead drug candidate ASN51 is a small molecule designed to block OGA, an enzyme that plays a role in protein aggregation. By preventing tau aggregation, the drug is intended to slow Alzheimer’s progression. In Phase 1 tests in healthy volunteers, Asceneuron said results showed its brain-penetrating drug was taken up by the central nervous system and hit a high percentage of its OGA target enzymes.” ~ learn more